. . . .

Interplay between FDA Law and Patent Law: Avoiding Indigestion After Belcher v. Hospira

  • 06 Jan 2022
  • (PST)

- Register for SVIPLA's January Webinar - 

Interplay Between FDA Law and Patent Law: Avoiding Indigestion after Belcher v. Hospira

Thursday, January 6, 2022
12:00 p.m. - 1:00 p.m. (PST)


1 unit of General MCLE credit is provided to SVIPLA Members.

Click Here to Join SVIPLA! 


SVIPLA is pleased to announce our January presentation "Interplay between FDA Law and Patent Law: Avoiding Indigestion After Belcher v. Hospira."

On September 1, 2021, the Federal Circuit issued its decision in Belcher Pharmaceuticals, LLC v. Hospira, Inc., affirming a finding of unenforceability of a patent for inequitable conduct, inferring intent based in part on inconsistent representations that were made by the patentee to the U.S. Food & Drug Administration versus the U.S. Patent & Trademark Office. This latest case is just one of many examples of the interplay between the FDA regulatory and USPTO patenting spheres.

Our speakers will discuss Belcher and other cases involving FDA/USPTO interplay, involving a range of considerations including patentability, duty of candor, infringement exemption under 271(e)(1), and patent term extension for regulatory approval delay.

About Our Speakers:

Suneel Arora is a Principal at Schwegman Lundberg Woessner. Suneel has established a 25-year track record as a collaborative counselor and pragmatic steward, capturing and curating IP of numerous industry-leading companies and successfully launched startup ventures. A Wisconsin native, he started his technology career as an integrated circuit engineer designing low-power ICs for power conversion and regulation, precision references, switched-capacitor filters, and analog-to-digital converters for implantable cardiac devices. Suneel applies his skills, honed on robust lifesaving designs without iteration, to his approach in crafting patents and portfolio strategies. 

Timothy Christman is a Principal at Schwegman Lundberg & Woessner, where he handles intellectual property matters for concepts ranging from the incremental to the revolutionary. Prior to joining Schwegman, Tim worked as a test engineer and later as a design engineer on active implantable medical devices. In addition to his medical device background, Tim is conversant in physics-oriented domains such as relating to imaging science, acoustics, electromagnetics, and spectroscopy, as well as electronics-related subject matter including device structures, circuits, fabrication techniques, and display technologies.

Piers Blewett is a principal at Schwegman Lundberg & Woessner. He is a Global Patent Fellow (admitted 2015) at the Federal Circuit Bar Association, and is a former Chief Patent Counsel, Vice President, and International General Counsel at Kimberly Clark Corporation. Piers’ practice includes strategic IP counseling, patent prosecution (US and foreign), patent validity, infringement analysis and opinions, risk assessment, global patent litigation, and IP due diligence work.

CLE: 1 hour CLE credit available (California) to SVIPLA Members.

You are encouraged to share this event with your contacts. After registration, you will receive detailed event information through email.

Silicon Valley Intellectual Property Law Association

© 2023 Silicon Valley Intellectual Property Law Association • All rights reserved
Designed by The ARRC™

Powered by Wild Apricot Membership Software